Abstract
BackgroundAccumulated studies have exploited the association between osteopontin (OPN) expression and survival of patients with gastric cancer (GC), however, the results were controversial. Thus, we performed a meta-analysis, aiming to investigate the prognostic role of OPN for GC patients and to explore the association between OPN and clinicalpathological features of GC.ResultsA total of ten studies involving 1775 patients were included in final meta-analysis. Of the included studies, nine were conducted on Asian patients and one was performed on Caucasian patients. Regarding OPN detection, immunohistochemistry (IHC) was used on tissue specimens in eight studies and enzyme linked immunosorbent assay (ELISA) was used on plasma specimens in two studies. The pooled data showed that high OPN expression was correlated with poor OS (HR = 1.59, 95% CI: 1.15–2.22, p = 0.006). Subgroup analyses demonstrated that OPN had enhanced prognostic value for Asian patients (HR = 1.64, 95% CI = 1.11–2.41, p = 0.012) and for patients receiving surgical resection (HR = 1.6, 95% CI = 1.04–2.48, p = 0.034). In addition, the results also showed that elevated OPN expression was associated with lymph node metastasis, TNM stage, depth of invasion, tumor size and distant metastasis in GC.MethodsRelevant studies were retrieved through PubMed, Embase and Web of Science. Combined hazard ratio (HR) and 95% confidence interval (CI) were calculated to assess the association between OPN and overall survival (OS). Subgroup analyses and publication bias were also conducted.ConclusionsOPN overexpression was correlated with poor OS and clinical features reflecting high aggressiveness in patients with GC. OPN was a promising prognostic biomarker for GC.
Highlights
Gastric cancer (GC) is the fourth most commonly diagnosed cancer and the third leading cause of cancer related deaths among all cancer types worldwide [1]
OPN overexpression was correlated with poor overall survival (OS) and clinical features reflecting high aggressiveness in patients with gastric cancer (GC)
These results demonstrate that OPN overexpression can be considered and validated as a useful prognostic biomarker and an indicator which represents the invasiveness of gastric cancer
Summary
Gastric cancer (GC) is the fourth most commonly diagnosed cancer and the third leading cause of cancer related deaths among all cancer types worldwide [1]. In 2012, there were 951,600 incident cases (6.75% of all new cancer cases) with 723,100 deaths [2]. The 5-year overall survival (OS) rate of GC is about 20% in most parts of the world [3], and prognosis is much worse for metastatic or recurrent GC than for localized disease. The median OS for metastatic GC is approximately one year, even when patients are treated with chemotherapy [4]. Accumulated studies have exploited the association between osteopontin (OPN) expression and survival of patients with gastric cancer (GC), the results were controversial. We performed a meta-analysis, aiming to investigate the prognostic role of OPN for GC patients and to explore the association between OPN and clinicalpathological features of GC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
